Teva Pharmaceutical Industries Ltd. this week won...

...a patent lawsuit in favor of its oncology drug Bendeka, which now won’t see generic competition until at least 2031. The legal battle between Teva, Mylan and three other generic drugmakers dates back to 2017. Bendeka, which launched in 2016, is FDA-approved to treat several cancers, including chronic lymphocytic leukemia, multiple myeloma and small cell lung cancer. In the pharmacy benefit, Bendeka holds preferred status for 11% of covered lives, growing to 13% with prior authorization and/or step therapy. It is not covered or not listed for 36% of insured lives.

SOURCE: MMIT Analytics, as of 4/29/20